心脏性休克:一个概述
Mohamed Toufic El Hussein1, Camila Mushaluk
1Author Affiliations: School of Nursing and Midwifery, Faculty of Health, Community & Education, Mount Royal University, Calgary, Canada (Dr El Hussein and Ms Mushaluk);Faculty of Nursing, University of Alberta (Dr El Hussein); and Acute Care Nurse Practitioner Medical Cardiology, Coronary Care Unit - Rockyview General Hospital, Calgary, Alberta, Canada (Dr El Hussein).
由于死亡率高,心脏性休克 (CS) 治疗需要改进. 本综述涵盖了CS病理生理学,并探讨了当前的药物治疗方法,重点关注血管活性和内性药物,以指导有效的治疗策略.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临界护理医学 临界护理医学
背景情况:
- 心脏性休克 (CS) 是一个重大的临床挑战,死亡率高.
- 目前对CS的治疗策略往往产生不理想的结果,需要进一步的研究.
- 了解CS病理生理学对于开发有针对性的干预措施至关重要.
研究的目的:
- 为了提供一个最新的,基于证据的对心脏性休克的审查.
- 为了检查CS的病理生理学.
- 讨论当前的药物治疗选择,特别是血管活性剂和无otropic 药物.
主要方法:
- 关于心脏性休克现有研究的文献综述.
- 关于CS病理生理学的证据综合.
- 在CS管理中使用的药物治疗剂的分析.
主要成果:
- 心脏性休克涉及复杂的多器官功能障碍.
- 血管活性和内类药物在血液动力学支持中发挥着关键作用.
- 最佳的药剂选择和定位是改善结果的关键.
结论:
- 有效管理心脏性休克需要对其病理生理学的全面了解.
- 药物治疗,特别是使用血管活性和内性药物,对于改善CS患者的生存率至关重要.
- 对新的治疗方法进行进一步的研究是有必要的,以减少CS死亡率.
相关概念视频
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Pathophysiology of Heart Failure
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Overview of the Heart
The heart's...
Cardiovascular Drugs: Classification based on Therapeutic Indications


